Is Biogen Inc. (BIIB) a Buy, Sell, or Hold?
Biogen Inc.
NASDAQ:BIIB
$191.95 USD
-$17.08 (-8.17%)
- Volume
- 3.9M
- Average Volume
- 1.2M
- Market Capitalization
- $28.34B
- P/E Ratio
- 20.49
- Dividend Yield
- 0.00%
- Price Target
- $225.00
- Year High
- $219.72
- Year Low
- $121.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.06
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Christopher A. Viehbacher |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | BIIB |
| CUSIP | 09062X103 |
| CIK | 0000875045 |
| Web | https://www.biogen.com |
| Phone | 617 679 2000 |
| Currency | USD |
| Employees | 7500 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.35 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.06 |
| Quick Ratio | 2.41 |
| Cash Ratio | 1.13 |
Sales & Book Value
| Annual Sales | $9.81B |
| Price / Sales | 2.87 |
| Cash Flow | 17.82 |
| Price / Cash Flow | 10.80 |
| Price / Book | 1.51 |
Price Target and Rating
| Average Stock Price Forecast | $225.00 |
| High Stock Price Forecast | $260.00 |
| Low Stock Price Forecast | $157.00 |
| Forecast Upside/Downside | -14.69% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 48 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $8.83 |
| Trailing P/E Ratio | 20.49 |
| PEG Ratio | -2.63 |
| P/E Growth | -2.63 |
| Net Income | $1.29B |
| Net Margin | 13.92% |
| Pretax Margin | 14.89% |
| Return on Equity | 7.55% |
| Return on Assets | 4.65% |
Financials Score
| AltmanZ Score | 3.49 |
| Piotroski Score | 5.00 |
| Working Capital | 6.19B |
| Total Assets | 29.48B |
| Ebit | 1.81B |
| Market Cap | 30.86B |
| Total Liabilities | 10.83B |
Poll Results
About Biogen Inc. (NASDAQ:BIIB) Stock
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMIC ... ADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
2026-07-14 17:29:08
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript
Biogen Backs Alzheimer's Tau Drug for Phase 3 Despite Trial Miss
2026-07-14 15:02:25
Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern.
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi
2026-07-14 13:16:05
BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.
Stocks Steady as Upbeat Inflation Battles IBM Earnings
2026-07-14 12:03:00
Stocks are cautiously higher midday, as cooler inflation helps investors forget about higher oil prices
2026-07-14 12:00:00
LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable a
Why Is Biogen Stock Falling Tuesday?
2026-07-14 11:49:02
Biogen Inc. (NASDAQ:BIIB) on Tuesday said it will advance investigational Alzheimer's therapy diranersen into Phase 3 testing after new Phase 2 data showed the tau-targeting treatment slowed clinical decline while producing significant biomarker reductions.
2026-07-14 11:15:00
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 /PRNewswire/ -- Eisai Co., Ltd.
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
2026-07-14 09:18:47
The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage trial, reduced cognitive decline in five of six Alzheimer's assessment tools and significantly cut levels of the toxic protein in the brain, researchers reported on Tuesday.
Frequently Asked Questions
-
What is the current Biogen Inc. (BIIB) stock price?
-
Biogen Inc.(NASDAQ:BIIB) stock price is $191.95 in the last trading session. During the trading session, BIIB stock reached the peak price of $219.72 while $121.05 was the lowest point it dropped to. The percentage change in BIIB stock occurred in the recent session was --8.17% while the dollar amount for the price change in BIIB stock was -$-17.08.
-
BIIB's industry and sector of operation?
-
The NASDAQ listed BIIB is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of BIIB?
-
Guy Hadari | Chief Information Officer
Priya Singhal | Executive Vice President & Head of Development
Ginger Gregory | Executive Vice President & Chief Human Resources Officer
Christopher A. Viehbacher | President, Chief Executive Officer & Director
Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations & Technology -
How many employees does BIIB have?
-
Number of BIIB employees currently stands at 7500. BIIB operates from 225 Binney Street, Cambridge, MA 02142, US.
-
Link for BIIB official website?
-
Official Website of BIIB is: https://www.biogen.com
-
How do I contact BIIB?
-
BIIB could be contacted at phone #617 679 2000 and can also be accessed through its website. BIIB operates from 225 Binney Street, Cambridge, MA 02142, US.
-
How many shares of BIIB are traded daily?
-
The average number of BIIB shares traded daily for last 3 months was 1.2M.
-
What is the market cap of BIIB currently?
-
The market value of BIIB currently stands at $28.34B with its latest stock price at $191.95